JARDIANCE® (Empagliflozin)
The content on this website is in relation to adult patients
Indications
Chronic kidney disease
JARDIANCE® is indicated in adults for the treatment of chronic kidney disease.1
Type 2 diabetes
JARDIANCE® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance
- in addition to other medicinal products for the treatment of diabetes 1
According to the 5.1 section of the SmPC, both improvement of glycaemic control and reduction of cardiovascular morbidity and mortality are an integral part of the treatment of type 2 diabetes.1
Heart failure
JARDIANCE® is indicated in adults for the treatment of symptomatic chronic heart failure.1
EMPA-KIDNEY Trial
The largest dedicated CKD SGLT2i trial to date1-3,6
JARDIANCE was evaluated in a broad patient population vs placebo1. EMPA-KIDNEY included patients with a wide range of underlying causes of CKD, many with co-morbidities across the spectrum of cardiovascular, kidney, or metabolic conditions. EMPA-KIDNEY included adult patients with an eGFR ≥20 to <45mL/min/1.73m2 or an eGFR ≥45 to <90mL/min/1.73m2 with a UACR ≥200mg/g, at risk of CKD progression.
Patient characteristics at baseline (N=6609)1
† History of diabetes defined as self-reported history of diabetes of any type, use glucose-lowering medication, or HbA1c ≥48mmol/mol (6.5%) at randomisation.
‡ Prior CV disease defined as self reported history of myocardial infarction, heart failure, stroke, TIA or PAD.
EMPA-KIDNEY is the only SGLT2i CKD trial to include the understudied type of patients with low eGFR and without albuminuria1-3,6
* Defined as low risk if there are no other markers of kidney disease or CKD.
Abbreviations
CKD: chronic kidney disease; CV: cardiovascular; CVD: cardiovascular disease; DKD: diabetic kidney disease; eGFR: estimated glomerular filtration rate; HbA1c: glycated haemoglobin; IgA: immunoglobulin A; PAD: peripheral arterial disease; RAASi: renin-angiotensin-aldosterone system inhibitor; SGLT2i: sodium-glucose co-transporter-2 inhibitor; T2D: type 2 diabetes mellitus; TIA: transient ischaemic attack; UACR: urinary albumin-to-creatinine ratio.
References
- Herrington WG, et al. N Engl J Med. 2023;388(2):117-127. (EMPA-KIDNEY results and the publication’s Supplementary Appendix).
- Heerspink H, et al. N Engl J Med. 2020;383:1436-1446.
- Perkovic V, et al. N Engl J Med. 2019;380:2295-2306.
- EMPA-KIDNEY Collaborative Group. Nephrol Dial Transplant 2022;371317-1329.
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. Kidney Int Suppl 2013;3:1.
- JARDIANCE Data on File (EMP 23-29).
PC-GB-108943 V2
March 2024